Head-to-head subgroup analysis of human milk–based fortifiers finds significant improvements in health and brain growth measure for preemies fed mother’s milk plus Prolacta’s fortifiers
Type: Press Releases
Topic(s): Growth Neurodevelopmental Outcomes Total Parenteral Nutrition (TPN) Use
Prolacta Bioscience reassures hospitals of the safety of its human milk-based nutritional products during the coronavirus pandemic
Type: Press Releases
Topic(s): Clinical Studies Clinical Studies on Prolact/Humavant CR Pasteurization Quality & Safety
Microbiome and gut-brain axis in premature infants focus of 2020 International Conference on Human Milk Science and Innovation
Type: Press Releases
Topic(s): Conferences and Events Microbiome
Despite worsening prematurity birth rate, odds of survival improving with NICU adoption of Prolacta's 100% human milk-based fortifiers
Type: Press Releases
Topic(s): Growth Mortality Neurodevelopmental Outcomes
Study Reveals an Exclusive Human Milk Diet With Prolact+ H2MF, Prolacta’s 100% Breastmilk-Based Fortifier, Substantially Reduces Costs Due to Complications in the NICU
Type: Press Releases
Topic(s): Cost Savings / Cost Effectiveness
Prolacta Bioscience Launches Women’s Leadership Development Academy
Type: Press Releases
Topic(s): Company
Preemie Health Expert Dr. Melinda Elliott Named Chief Medical Officer of Prolacta Bioscience
Type: Press Releases
Topic(s): Company
Smallest Preemies Can Achieve Catch-Up Growth by 2 Years of Age with Exclusive Human Milk Diet New Study Finds
Type: Press Releases
Topic(s): Growth Long-Term outcomes
Prolacta Bioscience® to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019
Type: Press Releases
Topic(s): Conferences and Events
